Imaging Human Melanoma Using a Novel Tc-99m-labeled Lactam Bridge-cyclized Alpha-MSH Peptide
Overview
Affiliations
In this study, the human melanoma targeting property of (99m)Tc(EDDA)-HYNIC-AocNle-CycMSHhex {hydrazinonicotinamide-8-aminooctanoic acid-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH2} was determined in M21 human melanoma-xenografts to demonstrate its potential for human melanoma imaging. The IC50 value of HYNIC-AocNle-CycMSHhex was 0.48±0.01nM in M21 human melanoma cells (1281receptors/cell). The M21 human melanoma uptake of (99m)Tc(EDDA)-HYNIC-AocNle-CycMSHhex was 4.03±1.25, 3.26±1.23 and 3.36±1.48%ID/g at 0.5, 2 and 4h post-injection, respectively. Approximately 92% of injected dose cleared out the body via urinary system at 2h post-injection. (99m)Tc(EDDA)-HYNIC-AocNle-CycMSHhex showed high tumor/blood, tumor/muscle and tumor/skin uptake ratios after 2h post-injection. The M21 human melanoma-xenografted tumor lesions were clearly visualized by SPECT/CT using (99m)Tc(EDDA)-HYNIC-AocNle-CycMSHhex as an imaging probe at 2h post-injection. Overall, (99m)Tc(EDDA)-HYNIC-AocNle-CycMSHhex exhibited favorable human melanoma imaging property, highlighting its potential as an imaging probe for human metastatic melanoma detection.
Mikulova M, Mikus P Pharmaceuticals (Basel). 2021; 14(2).
PMID: 33669938 PMC: 7924883. DOI: 10.3390/ph14020167.
Zhang C, Zhang Z, Merkens H, Zeisler J, Colpo N, Hundal-Jabal N Sci Rep. 2019; 9(1):13575.
PMID: 31537869 PMC: 6753210. DOI: 10.1038/s41598-019-50014-5.
Yang J, Xu J, Cheuy L, Gonzalez R, Fisher D, Miao Y Mol Pharm. 2019; 16(4):1694-1702.
PMID: 30763112 PMC: 6443429. DOI: 10.1021/acs.molpharmaceut.9b00025.
Ga-DOTA-GGNle-CycMSH targets the melanocortin-1 receptor for melanoma imaging.
Yang J, Xu J, Gonzalez R, Lindner T, Kratochwil C, Miao Y Sci Transl Med. 2018; 10(466).
PMID: 30404861 PMC: 6383514. DOI: 10.1126/scitranslmed.aau4445.
Farzanefar S, Etemadi R, Shirkhoda M, Mahmoodzadeh H, Erfani M, Fallahi B Asia Ocean J Nucl Med Biol. 2018; 6(2):155-160.
PMID: 29998149 PMC: 6038966. DOI: 10.22038/aojnmb.2018.30101.1204.